K. granulomatis (previously Calymmatobacterium granulomatis), the agent of donovanosis - reported therapeutic agents, tetracycline and co-trimoxazole
K. ornitholytica, K. oxytoca, K. planticola, K. pneumoniae, K. ozaenae, K. terrigena - associated with UTI, bacteraemia, wound infection, respiratory tract infection - reported susceptibilities, beta-lactams, aminoglycosides, fluoroquinolones - susceptibilities vary - multiresistant strains reported - nosocomial outbreaks reported
K. rhinoscleromatis - the agent of rhinoscleroma - reported susceptible to ciprofloxacin, rifampicin, co-trimoxazole
References - Carter, J.S., Bowden, F.J., Bastian, I., Myers, G.M., Sripkash, K.S., Kemp, D.J. (1999). Phylogenetic evidence for reclassification of Calymmatobacterium granulomatis as Klebsiella granulomatis comb. nov. Int. J. syst. Bact. 49, 1695-1700. - Chetoui, H., Delhalle, E., Melin, P., Sabri, A., Thonart, P., De Mol, P. (1999). Epidemiological typing of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates by pulsed-field gel electrophoresis and antibiotic susceptibility patterns. Res. Microbiol. 150, 265-272. - Miller, R.H., Shulman, J.B., Canalis, R.F., Ward, P.H. (1979). Klebsiella rhinoscleromatis: a clinical and pathogenic enigma. Otolaryngol. head neck Surg. 87, 212-221.
